Scinai Immunotherapeutics
SCNI
5 hedge funds and large institutions have $7.09K invested in Scinai Immunotherapeutics in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
44% less funds holding
Funds holding: 9 → 5 (-4)
87% less capital invested
Capital invested by funds: $54.7K → $7.09K (-$47.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$49.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$692 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$278 |
| 4 |
MSG
Main Street Group
Glen Allen,
Virginia
|
-$59 |
| 5 |
GRP
Global Retirement Partners
San Rafael,
California
|
-$14 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
RhumbLine Advisers
Boston,
Massachusetts
| $5.85K | +$1.97K | +515 | +45% |
|
2
Morgan Stanley
New York
| $880 | – | – | – |
|
3
Credit Agricole
Montrouge Cedex,
France
| $145 | – | – | – |
|
|
APC
4
Aspire Private Capital
Cornelius,
North Carolina
| $110 | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $104 | -$692 | -181 | -86% |
|
|
SM
6
Sabby Management
Miami Beach,
Florida
| – | -$49.6K | -17,828 | Closed |
|
|
7
Bank of America
Charlotte,
North Carolina
| – | -$278 | -100 | Closed |
|
|
MSG
8
Main Street Group
Glen Allen,
Virginia
| – | -$59 | -20 | Closed |
|
|
GRP
9
Global Retirement Partners
San Rafael,
California
| – | -$14 | -5 | Closed |
|
SCNI Hedge Fund Activity: Q3 2024 in Review
5 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2024, worth a combined $7.09K — down 87% from $54.7K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SCNI and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was RhumbLine Advisers, adding an estimated $1.97K. The largest seller was Sabby Management, exiting entirely with an estimated $49.6K sold.
- 5 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2024, down from 9 in Q2 2024.
- Funds reported $7.09K of Scinai Immunotherapeutics stock for Q3 2024, down 87% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q3 2024 and 4 closed out, a net change of -4 holders.
- The largest Scinai Immunotherapeutics buyer in Q3 2024 was RhumbLine Advisers, an estimated $1.97K added.
- The largest Scinai Immunotherapeutics seller in Q3 2024 was Sabby Management, an estimated $49.6K sold.
Based on aggregated 13F filings for Q3 2024.